Evidence map›Paper›PMID 38257256›Full record

ArticleMolecules (Basel, Switzerland)2024

Mode of Antibacterial Action of Tomatidine C3-Diastereoisomers.

Jean-Philippe Langlois, Audrey Larose, Eric Brouillette, Julien A Delbrouck, Pierre-Luc Boudreault, François Malouin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cryptotanshinone inhibitsVirulence · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jean-Philippe LangloisDépartement de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Audrey LaroseDépartement de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Eric BrouilletteDépartement de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Julien A DelbrouckDépartement de Pharmacologie et Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Pierre-Luc BoudreaultDépartement de Pharmacologie et Physiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.ORCID 0000-0002-2032-7970
François MalouinDépartement de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.ORCID 0000-0001-5031-345X
Université de Sherbrooke · CA

Funding

Aligo Innovation PSO-PSVT-2d, INVA-029Amorchem Therapeutics, Inc SynerQc-SYN-185Cystic Fibrosis Canada 558321Fonds de Recherche du Québec - Nature et Technologies to JPLMitacs to JPL, JADNatural Sciences and Engineering Research Council 2020-04811 to FMNatural Sciences and Engineering Research Council 2022-04028 to PLBQuébec Consortium for Drug Discovery SynerQc-SYN-185
6 · The paper itself

Abstract

Tomatidine (TO) is a natural narrow-spectrum antibiotic acting on the

Indexed as

Escherichia coliStaphylococcus aureusAdenosine TriphosphateAnti-Bacterial AgentsTomatineAdenosine TriphosphateAnti-Bacterial AgentstomatidineTomatineantibiotic mode of actionATP synthase inhibitorbactericidal activityEscherichia colimembrane fluiditymembrane potentialreactive oxygen speciesStaphylococcus aureustomatidine

Identifiers

PMID38257256
PMCPMC10821064
OpenAlexW4390696698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.